Codeine’s plasma half-life in healthy adults falls in the range of roughly two to three and a half hours, depending on the study and the individual. One well-cited pharmacokinetic study in healthy volunteers measured a mean half-life of about two and a half hours, while other references place the terminal half-life at three to three and a half hours. That spread is not a contradiction; it reflects natural variation in liver function, genetics, and how the measurement is done. But the half-life figure alone does not tell you how long codeine’s effects last, when your body is truly clear of the drug, or why one person might process it twice as fast as another.
What the Half-Life Actually Tells You
A drug’s half-life is the time it takes for the concentration in your blood to drop by half. After one half-life of codeine, about half the dose is still circulating. After two half-lives (roughly five to seven hours), about a quarter remains. The general rule of thumb in pharmacology is that a drug is considered essentially eliminated after four to five half-lives, which for codeine works out to roughly 10 to 18 hours for most adults. That tracks well with what studies show: one plasma pharmacokinetics study found that codeine was no longer detectable in plasma about 12 to 16 hours after an oral dose, depending on the sensitivity of the test used.1Clinical Chemistry. Plasma and Oral Fluid Pharmacokinetics and Pharmacodynamics after Oral Codeine Administration
After you swallow a codeine tablet, blood levels typically peak within about an hour.2A Practice of Anesthesia for Infants and Children. Pharmacokinetics and Pharmacology of Drugs Used in Children – Section: Codeine Intramuscular injection gets there faster, peaking around 30 minutes. Pain relief generally tracks with those blood levels, fading noticeably within four to six hours after a single oral dose. But the drug and its metabolites linger in smaller amounts for much longer than the pain relief does, which matters for drug testing and for understanding drug interactions.
How Your Liver Breaks Down Codeine
Codeine itself is actually a weak painkiller. Most of its analgesic effect comes from the fact that your liver converts a portion of the codeine into morphine, which is a much more potent opioid. This conversion is handled by a liver enzyme called CYP2D6.3PubMed Central. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype The morphine then gets further broken down into compounds called glucuronides, which the kidneys filter out.
CYP2D6 is not the only pathway. Another liver enzyme, CYP3A4, handles a separate breakdown route that produces norcodeine, a metabolite with very little painkilling activity. A third pathway converts codeine directly into codeine-6-glucuronide, which the body excretes through urine.4PubMed Central. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects The bottom line is that codeine splits into a family of metabolites, and the CYP2D6-to-morphine pathway is the one that determines whether the drug works for pain and how intensely you feel its opioid effects.
That metabolite profile also explains why codeine’s half-life does not capture the full picture of how long the drug’s byproducts stay in your body. Morphine itself has its own half-life, and its glucuronide metabolites persist even longer. Forensic and post-mortem studies have measured codeine and its metabolites in blood, tissue, and body fluids, confirming that the metabolic footprint extends well past the point where codeine itself disappears from plasma.5PubMed. Post-mortem levels and tissue distribution of codeine, codeine-6-glucuronide, norcodeine, morphine and morphine glucuronides in a series of codeine-related deaths
Genetic Variation Can Dramatically Shift the Timeline
The CYP2D6 enzyme does not work at the same speed in everyone. People inherit different versions of the gene that codes for this enzyme, and the differences are large enough to change whether codeine works, whether it’s dangerous, or whether its half-life and metabolite levels deviate sharply from the average.
At one extreme are “poor metabolizers,” who carry gene variants that produce little or no functional CYP2D6. These individuals convert almost no codeine into morphine, which means they get minimal pain relief from the drug. At the other extreme are “ultra-rapid metabolizers,” who carry extra copies of the CYP2D6 gene and convert codeine to morphine much faster and more completely than normal. A pharmacokinetic study comparing these groups found that ultra-rapid metabolizers had about 50% higher morphine blood levels than normal metabolizers after the same 30 mg dose. Over 90% of the ultra-rapid group reported feeling sedated, compared with half of the normal-metabolizer group.6PubMed. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
The codeine itself may clear from blood at a similar rate regardless of metabolizer type, but the amount of morphine generated, and therefore the intensity and duration of the opioid effect, varies enormously. This is why clinical pharmacogenetics guidelines describe codeine’s effectiveness and safety as being “governed by” CYP2D6 genetic variants.3PubMed Central. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype A reported case of severe codeine intoxication was linked to ultra-rapid CYP2D6 metabolism, where the patient generated dangerously high morphine levels from what would normally be a routine dose.7PubMed. Codeine intoxication associated with ultrarapid CYP2D6 metabolism
A pragmatic clinical trial found that when doctors used CYP2D6 genetic testing to guide prescribing for intermediate and poor metabolizers, patients initially given codeine or a similar drug saw meaningfully better pain control after being switched to an alternative, compared with patients who received usual care without genetic guidance.8Genetics in Medicine. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial The takeaway: if codeine never seems to relieve your pain, or if you feel unusually drowsy after a standard dose, your CYP2D6 genetics may be the reason.
When the Half-Life Gets Longer
Several conditions can slow down codeine clearance, effectively stretching its half-life and raising the risk of accumulation with repeated dosing.
Liver disease is the most important one. Because the liver is responsible for nearly all of codeine’s metabolism, reduced liver function means the drug and its metabolites can build up unpredictably. In patients with liver failure, codeine may either fail to produce enough morphine for pain relief (because the CYP2D6 pathway is impaired) or, paradoxically, lead to dangerous morphine accumulation if the later steps that clear morphine from the body are also compromised. A systematic review of opioid use in liver disease patients noted that codeine can cause respiratory depression in this group due to metabolite accumulation, and recommended that patients with liver failure use a different analgesic altogether.9Hepatitis Monthly. Opioid Drugs in Patients With Liver Disease: A Systematic Review – Section: Codeine
Age is another factor. Infants and very young children metabolize codeine differently from older children and adults. After rectal administration, the elimination half-life in children was measured at about 2.6 hours, but in infants it was substantially longer at roughly 4.6 hours, suggesting that repeated doses need to be spaced further apart in the youngest patients.2A Practice of Anesthesia for Infants and Children. Pharmacokinetics and Pharmacology of Drugs Used in Children – Section: Codeine The combination of immature liver enzymes and unpredictable CYP2D6 activity in children is part of the reason that regulatory agencies in several countries have restricted codeine use in pediatric patients, particularly after tonsillectomies or adenoidectomies. Kidney impairment can also delay the excretion of codeine’s metabolites, since the glucuronide byproducts are primarily eliminated through urine.
Drug Interactions That Change the Math
Even if your genetics predict normal CYP2D6 activity, certain medications can temporarily shut down or slow the enzyme, a phenomenon called “phenoconversion.” In practical terms, you may genetically be a normal metabolizer, but if you are taking a drug that strongly inhibits CYP2D6, your body behaves as if you were a poor metabolizer. This can reduce codeine’s pain-relieving effectiveness while simultaneously changing the balance of metabolites in your system.10PubMed Central. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine
Common CYP2D6 inhibitors include certain antidepressants (fluoxetine, paroxetine, and bupropion are potent ones), the heart rhythm drug quinidine, and some antihistamines. If you are taking one of these alongside codeine, the effective half-life of codeine may appear longer simply because less of it is being actively broken down, and the analgesic effect may be blunted because less morphine is being produced.
One study specifically examined codeine metabolism in people maintained on methadone versus buprenorphine, finding that methadone inhibited both the CYP2D6 pathway and the glucuronidation pathway for codeine.4PubMed Central. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects This kind of dual inhibition is particularly relevant for people in opioid treatment programs who might be prescribed codeine for acute pain, as it changes how the drug is processed in multiple ways at once.
How Long Codeine Shows Up on Drug Tests
The half-life determines how quickly codeine leaves your bloodstream, but drug tests are designed to catch metabolites at trace levels long after the parent drug’s effects have worn off. The detection window varies enormously depending on what type of sample is being tested.
In urine, codeine and its metabolites are excreted rapidly, with the bulk appearing in the first 24 hours after a dose.11PubMed. Forensic drug testing for opiates, III. Urinary excretion rates of morphine and codeine following codeine administration Standard workplace urine drug screens can generally detect codeine for one to three days after use, depending on the dose and the cutoff concentration used by the testing lab. Because codeine produces morphine as a metabolite, a codeine dose can also trigger a positive result on tests that screen for morphine.
Oral fluid (saliva) testing gives a shorter window. The mean half-life of codeine in oral fluid matched that in plasma at about 2.2 hours, but detection times varied with the cutoff. At a very low cutoff of 2.5 micrograms per liter, codeine was detectable in saliva for an average of 21 hours. When using the higher cutoff proposed for federal workplace testing (40 micrograms per liter), the detection window shrank to only about 7 hours.1Clinical Chemistry. Plasma and Oral Fluid Pharmacokinetics and Pharmacodynamics after Oral Codeine Administration
Blood testing is the most direct measure and also the shortest window. Codeine falls below detectable levels in plasma within roughly 12 to 16 hours for most people, as noted earlier.1Clinical Chemistry. Plasma and Oral Fluid Pharmacokinetics and Pharmacodynamics after Oral Codeine Administration
Hair Testing and Long-Term Detection
Hair testing operates on a completely different timescale and has nothing to do with the drug’s plasma half-life. As codeine circulates in your blood, trace amounts get incorporated into growing hair follicles. A study that gave volunteers a single 120 mg dose of codeine found the drug detectable in the nearest-to-scalp centimeter of hair within 30 minutes of dosing. More remarkably, codeine remained detectable in hair for at least 10 weeks after that single dose. When volunteers took 30 mg three times daily for five days, the concentrations in hair were higher, and the detection window extended correspondingly.12PubMed. Codeine disposition in human hair after single and multiple doses
Hair grows at roughly one centimeter per month, so a standard hair drug test that analyzes the three centimeters closest to the scalp is looking at a roughly three-month window. This means that even though codeine’s plasma half-life is just a few hours, your hair can record evidence of use for months.
Why Published Half-Life Numbers Vary
If you search for codeine’s half-life, you will find numbers ranging from about two hours to three and a half hours, and it can be confusing to see different sources report different figures with apparent confidence. The variation comes from several legitimate sources.
One study of healthy Caucasian volunteers measured a mean half-life of about 2.6 hours.13British Journal of Clinical Pharmacology. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine A plasma pharmacokinetics study that also looked at oral fluid found a mean of about 2.2 hours.1Clinical Chemistry. Plasma and Oral Fluid Pharmacokinetics and Pharmacodynamics after Oral Codeine Administration A pediatric anesthesia reference reports the terminal half-life as 3 to 3.5 hours in adults.2A Practice of Anesthesia for Infants and Children. Pharmacokinetics and Pharmacology of Drugs Used in Children – Section: Codeine
Some of this spread comes from the difference between the “distribution half-life” (how quickly the drug spreads from blood into tissues) and the “terminal half-life” (how quickly it is ultimately eliminated from the body). The terminal half-life is usually the longer number and is what most clinical references report. Sample size, dosing protocol, the assay used to measure drug levels, and the genetic makeup of the study population all contribute to the range. For practical purposes, saying codeine’s half-life is roughly two and a half to three and a half hours captures the realistic span for most healthy adults. Your personal number falls somewhere in that range and could sit outside it if your liver function, genetics, or medications push it in either direction.
Bioavailability and What Gets Into Your System
Half-life describes how fast your body eliminates codeine, but bioavailability describes how much of the dose reaches your bloodstream in the first place. When codeine is swallowed as a tablet, not all of it makes it into circulation. Some is broken down by the liver during what pharmacologists call “first-pass metabolism” before it even reaches the general blood supply. Studies in healthy volunteers have measured oral bioavailability at roughly 50 to 55%.2A Practice of Anesthesia for Infants and Children. Pharmacokinetics and Pharmacology of Drugs Used in Children – Section: Codeine This means that if you take a 30 mg tablet, only about 15 to 17 mg effectively enters your bloodstream.
This matters because two people taking the same pill may absorb different amounts depending on how much food is in their stomach, how quickly things move through their gut, and how active their liver’s first-pass enzymes are. Someone with faster gut transit might absorb less, while someone with slower transit might absorb more but also reach peak levels later. These absorption differences interact with the half-life: if you absorb the drug more slowly, the effective window of activity may feel longer even though the elimination rate once it reaches your blood is similar.
For comparison, intramuscular or intravenous routes bypass the gut entirely, delivering nearly all the drug into the bloodstream. This is why injectable codeine reaches peak levels in about half the time that oral codeine does, and why the onset of pain relief is faster. The half-life after injection is similar to oral dosing, but the shape of the blood-level curve looks different because the drug gets in faster and starts declining sooner.